PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31137797-4 2019 Our results from an in-vitro model of osteoarthritis indicate that genistein inhibits the IL-1beta-induced expression of the catabolic factors nitric oxide synthase 2 (NOS2), cyclooxygenase 2 (COX-2), and matrix metalloproteinases (MMPs). Genistein 67-76 prostaglandin-endoperoxide synthase 2 Homo sapiens 175-191 8393774-5 1993 AG18 (or genistein) blocked agonist induction of luteinization and of PGS-2 mRNA and protein when present during the first 2 h (0-2 h) of follicle incubation, but failed to block these events if added for the last 2 h (5-7 h of incubation). Genistein 9-18 prostaglandin-endoperoxide synthase 2 Homo sapiens 70-75 15194215-0 2004 Inhibition of cyclooxygenase-2 activity in head and neck cancer cells by genistein. Genistein 73-82 prostaglandin-endoperoxide synthase 2 Homo sapiens 14-30 9580637-2 1998 Tyrosine kinase inhibitor, genistein, and tyrosine phosphatase inhibitor, phenylarsine oxide (PAO), blocked TNF-alpha-mediated induction of PGHS-2 mRNA in these cells. Genistein 27-36 prostaglandin-endoperoxide synthase 2 Homo sapiens 140-146 31137797-4 2019 Our results from an in-vitro model of osteoarthritis indicate that genistein inhibits the IL-1beta-induced expression of the catabolic factors nitric oxide synthase 2 (NOS2), cyclooxygenase 2 (COX-2), and matrix metalloproteinases (MMPs). Genistein 67-76 prostaglandin-endoperoxide synthase 2 Homo sapiens 193-198 24742714-10 2014 The above findings, taken together, suggest that genistein inhibits TPA-induced COX-2 expression in MCF10A cells by blocking ERK-mediated phosphorylation of p65 and its subsequent interaction with CBP and TBP. Genistein 49-58 prostaglandin-endoperoxide synthase 2 Homo sapiens 80-85 24742714-0 2014 Genistein inhibits phorbol ester-induced NF-kappaB transcriptional activity and COX-2 expression by blocking the phosphorylation of p65/RelA in human mammary epithelial cells. Genistein 0-9 prostaglandin-endoperoxide synthase 2 Homo sapiens 80-85 25447760-4 2014 The treatment of LPS-stimulated macrophages with 150 kGy gamma-irradiated genistein resulted in a significant decrease in cyclooxygenase-2 levels, as well as the expression of cell surface molecules, such as CD80 and CD86. Genistein 74-83 prostaglandin-endoperoxide synthase 2 Homo sapiens 122-138 24742714-2 2014 In the present study, we have investigated the effects of genistein on phorbol ester-induced expression of cyclooxygenase-2 (COX-2) that plays an important role in the pathophysiology of inflammation-associated carcinogenesis. Genistein 58-67 prostaglandin-endoperoxide synthase 2 Homo sapiens 107-123 24491678-4 2014 Our results indicated that genistein inhibited the production of nitric oxide (NO) and prostaglandin E2 at non-toxic concentrations by inhibiting inducible NO synthase and cyclooxygenase-2 expression. Genistein 27-36 prostaglandin-endoperoxide synthase 2 Homo sapiens 172-188 24742714-2 2014 In the present study, we have investigated the effects of genistein on phorbol ester-induced expression of cyclooxygenase-2 (COX-2) that plays an important role in the pathophysiology of inflammation-associated carcinogenesis. Genistein 58-67 prostaglandin-endoperoxide synthase 2 Homo sapiens 125-130 24742714-3 2014 Pretreatment of cultured human breast epithelial (MCF10A) cells with genistein reduced COX-2 expression induced by 12-O-tetradecanoylphorbol-13-acetate (TPA). Genistein 69-78 prostaglandin-endoperoxide synthase 2 Homo sapiens 87-92 21341175-5 2011 Four flavonoids (flavone, isorhamnetin, daidzein, and genistein) inhibited significantly LPS-induced COX-2 expression, while mPGES-1 expression was downregulated by kaempferol and isorhamnetin. Genistein 54-63 prostaglandin-endoperoxide synthase 2 Homo sapiens 101-106 17052999-0 2007 Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells. Genistein 50-59 prostaglandin-endoperoxide synthase 2 Homo sapiens 63-68 17052999-3 2007 In a series of experiments we examined a potential synchronous action of n-3 PUFA and genistein in down-regulating COX-2 expression to diminish prostaglandin E(2) (PGE(2)) production in MDA-MB-231 human breast cancer cells. Genistein 86-95 prostaglandin-endoperoxide synthase 2 Homo sapiens 115-120 17052999-9 2007 Genistein combined with AA reversed the effects of AA alone on the expression of COX-2 and NFkappaB. Genistein 0-9 prostaglandin-endoperoxide synthase 2 Homo sapiens 81-86 22289529-0 2011 Involvement of nuclear factor kappaB (NF-kappaB) in the downregulation of cyclooxygenase-2 (COX-2) by genistein in gastric cancer cells. Genistein 102-111 prostaglandin-endoperoxide synthase 2 Homo sapiens 74-90 22289529-0 2011 Involvement of nuclear factor kappaB (NF-kappaB) in the downregulation of cyclooxygenase-2 (COX-2) by genistein in gastric cancer cells. Genistein 102-111 prostaglandin-endoperoxide synthase 2 Homo sapiens 92-97 22289529-3 2011 Genistein treatment inhibited cell proliferation and induced apoptosis in a dose- and time-dependent manner; Western blotting analysis indicated a significant dose-dependent decrease in COX-2 protein levels. Genistein 0-9 prostaglandin-endoperoxide synthase 2 Homo sapiens 186-191 22289529-6 2011 Suppression of COX-2 protein may be important for the antiproliferative and proapoptotic effects of genistein in BGC-823 cells, and these effects may be partly mediated through the NF-kappaB pathway. Genistein 101-110 prostaglandin-endoperoxide synthase 2 Homo sapiens 15-20 19127598-3 2009 In the cell culture experiments, genistein decreased cyclooxygenase-2 (COX-2) mRNA and protein expression in both human PCa cell lines (LNCaP and PC-3) and primary prostate epithelial cells and increased 15-hydroxyprostaglandin dehydrogenase (15-PGDH) mRNA levels in primary prostate cells. Genistein 33-42 prostaglandin-endoperoxide synthase 2 Homo sapiens 53-69 19127598-3 2009 In the cell culture experiments, genistein decreased cyclooxygenase-2 (COX-2) mRNA and protein expression in both human PCa cell lines (LNCaP and PC-3) and primary prostate epithelial cells and increased 15-hydroxyprostaglandin dehydrogenase (15-PGDH) mRNA levels in primary prostate cells. Genistein 33-42 prostaglandin-endoperoxide synthase 2 Homo sapiens 71-76 17052999-1 2007 N-3 polyunsaturated fatty acids (PUFA) and genistein have been associated with lowered cancer risk by reducing inflammatory prostanoids, cyclooxygenase-2 (COX-2) activity, and altering cell signaling. Genistein 43-52 prostaglandin-endoperoxide synthase 2 Homo sapiens 137-153 17052999-1 2007 N-3 polyunsaturated fatty acids (PUFA) and genistein have been associated with lowered cancer risk by reducing inflammatory prostanoids, cyclooxygenase-2 (COX-2) activity, and altering cell signaling. Genistein 43-52 prostaglandin-endoperoxide synthase 2 Homo sapiens 155-160 16870006-4 2006 Genistein, daidzein and equol were found to inhibit COX-2 expression induced by phorbol 12-myristate 13-acetate (PMA). Genistein 0-9 prostaglandin-endoperoxide synthase 2 Homo sapiens 52-57 16889690-4 2006 Genistein significantly inhibited 12-Otetradecanoylphorbol-13-acetate (TPA)-induced cyclooxygenase-2 activity and protein expression at the concentrations of 10 (p < 0.05), 25 (p < 0.05) and 50 mM (p < 0.01). Genistein 0-9 prostaglandin-endoperoxide synthase 2 Homo sapiens 84-100 10946303-3 2000 Tyrosine kinase inhibitors (genistein or herbimycin) or phosphoinositide-specific phospholipase C inhibitor (U73122) blocked TNF-alpha-induced COX-2 expression. Genistein 28-37 prostaglandin-endoperoxide synthase 2 Homo sapiens 143-148 16585150-2 2006 Recent studies suggest that genistein and other dietary compounds that prevent cancer may enhance the efficacy of cancer therapeutics by modifying the activity of key cell proliferation and survival pathways, such as those controlled by Akt, nuclear factor-kappaB, and cyclooxygenase-2. Genistein 28-37 prostaglandin-endoperoxide synthase 2 Homo sapiens 269-285 15896711-0 2005 Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Genistein 34-43 prostaglandin-endoperoxide synthase 2 Homo sapiens 145-150 15896711-3 2005 There is an emerging evidence that genistein, soy-derived phytoestrogen, may have potential as a chemotherapeutic agent capable of inducing apoptosis or suppressing tumor promoting proteins such as cyclooxygenase-2 (COX-2). Genistein 35-44 prostaglandin-endoperoxide synthase 2 Homo sapiens 198-214 15896711-3 2005 There is an emerging evidence that genistein, soy-derived phytoestrogen, may have potential as a chemotherapeutic agent capable of inducing apoptosis or suppressing tumor promoting proteins such as cyclooxygenase-2 (COX-2). Genistein 35-44 prostaglandin-endoperoxide synthase 2 Homo sapiens 216-221 15896711-5 2005 The present study focused on the correlation of AMPK and COX-2 in combined cytotoxicity of 5-FU and genistein, since AMPK is known as a primary cellular homeostasis regulator and a possible target molecule of cancer treatment, and COX-2 as cell proliferation and anti-apoptotic molecule. Genistein 100-109 prostaglandin-endoperoxide synthase 2 Homo sapiens 57-62 15896711-5 2005 The present study focused on the correlation of AMPK and COX-2 in combined cytotoxicity of 5-FU and genistein, since AMPK is known as a primary cellular homeostasis regulator and a possible target molecule of cancer treatment, and COX-2 as cell proliferation and anti-apoptotic molecule. Genistein 100-109 prostaglandin-endoperoxide synthase 2 Homo sapiens 231-236 15896711-6 2005 Our results demonstrated that the combination of 5-FU and genistein abolished the up-regulated state of COX-2 and prostaglandin secretion caused by 5-FU treatment in HT-29 colon cancer cells. Genistein 58-67 prostaglandin-endoperoxide synthase 2 Homo sapiens 104-109 15567061-2 2005 PMA-induced COX-2 expression was attenuated by PKC inhibitors (Go 6976 and Ro 31-8220), a Ras inhibitor (manumycin A), a Raf-1 inhibitor (GW 5074), a MEK inhibitor (PD 098059), and an NF-kappaB inhibitor (PDTC), but not by a tyrosine kinase inhibitor (genistein) or a p38 MAPK inhibitor (SB 203580). Genistein 252-261 prostaglandin-endoperoxide synthase 2 Homo sapiens 12-17 10946303-6 2000 The 12-O-tetradecanoylphorbol 13-acetate (TPA), a PKC activator, also stimulated COX-2 expression, this effect being inhibited by genistein or herbimycin. Genistein 130-139 prostaglandin-endoperoxide synthase 2 Homo sapiens 81-86 10946303-7 2000 NF-kappaB DNA-protein binding and COX-2 promoter activity were enhanced by TNF-alpha, and these effects were inhibited by genistein, U73122, staurosporine, or pyrolidine dithiocarbamate. Genistein 122-131 prostaglandin-endoperoxide synthase 2 Homo sapiens 34-39 10946303-8 2000 TPA stimulated both NF-kappaB DNA-protein binding and COX-2 promoter activity, these effects being inhibited by genistein, herbimycin, or pyrolidine dithiocarbamate. Genistein 112-121 prostaglandin-endoperoxide synthase 2 Homo sapiens 54-59 10783318-7 2000 Chemopreventive agents such as quercetin, kaempferol, genistein, resveratrol and resorcinol, all having a common resorcin moiety, were found to effectively suppress the COX-2 promoter activity with and without TGFalpha-stimulation in DLD-1 cells. Genistein 54-63 prostaglandin-endoperoxide synthase 2 Homo sapiens 169-174 10617676-3 2000 The tyrosine kinase inhibitors (genistein and tyrphostin AG126) and phosphatidylcholine-phospholipase C inhibitor (D-609) prevented IL-1beta-induced prostaglandin E(2) (PGE(2)) release and COX-2 expression, whereas U-73122 (a phosphatidylinositol-phospholipase C inhibitor) and propranolol (a phosphatidate phosphohydrolase inhibitor) had no effect. Genistein 32-41 prostaglandin-endoperoxide synthase 2 Homo sapiens 189-194 10354065-4 1999 Genistein, a tyrosine kinase inhibitor, suppressed both the basal and stimulated expression of cyclooxygenase-2 in HaCaT cells. Genistein 0-9 prostaglandin-endoperoxide synthase 2 Homo sapiens 95-111